Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Gould

Showing results (671-680 of 696) with videos related to

Pageof 70
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 12, 2004
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chainsDong-Ming Shen, Min Shu, Sander G Mills, et al.
European Journal of Neurology|April 25, 2024
Cost-effectiveness of acceptance and commitment therapy for people living with motor neuron disease, and their health-related quality of lifeAnju D Keetharuth, Rebecca L Gould, Christopher J McDermott, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activityJ J Hale, R J Budhu, E B Holson, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanesP E Finke, L C Meurer, B Oates, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic propertiesDooseop Kim, Liping Wang, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infectionD Kim, L Wang, C G Caldwell, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infectionD Kim, L Wang, C G Caldwell, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidinesChristopher L Lynch, Amy L Gentry, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanesC P Dorn, P E Finke, B Oates, et al.
Journal of Neuroendocrinology|December 27, 2024
Earlier diagnosis of small intestine neuroendocrine tumours (SI-NETs) through transformation of the South Wales NET serviceHarriet L Gould, Kapish Amin, Thanos Karategos, et al.
Pageof 70

Showing results (671-680 of 696) with videos related to

Sort By:
Pageof 70
Bioorganic & Medicinal Chemistry Letters|March 12, 2004
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chainsDong-Ming Shen, Min Shu, Sander G Mills, et al.
European Journal of Neurology|April 25, 2024
Cost-effectiveness of acceptance and commitment therapy for people living with motor neuron disease, and their health-related quality of lifeAnju D Keetharuth, Rebecca L Gould, Christopher J McDermott, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activityJ J Hale, R J Budhu, E B Holson, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanesP E Finke, L C Meurer, B Oates, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic propertiesDooseop Kim, Liping Wang, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infectionD Kim, L Wang, C G Caldwell, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infectionD Kim, L Wang, C G Caldwell, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidinesChristopher L Lynch, Amy L Gentry, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanesC P Dorn, P E Finke, B Oates, et al.
Journal of Neuroendocrinology|December 27, 2024
Earlier diagnosis of small intestine neuroendocrine tumours (SI-NETs) through transformation of the South Wales NET serviceHarriet L Gould, Kapish Amin, Thanos Karategos, et al.
Pageof 70